Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), is a metabolic disorder driven by insulin resistance and elevated male hormones, not simply a reproductive condition. For decades, doctors focused on the ovarian symptoms and fertility issues, but new research reveals that GLP-1 receptor agonists (a class of diabetes medications) can address the underlying metabolic dysfunction that causes the condition. This shift in understanding is changing how doctors treat millions of women worldwide.

What Is PMOS, and Why Was It Misunderstood for So Long?

PMOS affects 10% to 13% of women, yet about 70% of those affected remain undiagnosed, according to the World Health Organization. The condition was named for polycystic ovaries, which led doctors to treat it as primarily a reproductive disorder. However, experts now understand that polycystic ovaries are actually a symptom, not the root cause.

"Instead of just a reproductive disorder, PCOS is much more of a metabolic disorder, characterized by elevated male hormones, insulin resistance, and glucose dysfunction," explained Karen Elkind-Hirsch, PhD, senior clinical scientist at Dexcom, an American medical device company that manufactures continuous glucose monitoring systems.

Karen Elkind-Hirsch, PhD, Senior Clinical Scientist at Dexcom

The driving force behind PMOS is elevated insulin levels, which stimulate the ovaries to produce androgens (male hormones). Excess androgens are linked to insulin resistance and obesity, creating a self-reinforcing cycle: hormonal dysregulation can cause weight gain, and weight gain can worsen hormonal dysregulation.

Why Should Women With PMOS Care Beyond Fertility?

While infertility is a well-known consequence of PMOS, the condition carries serious long-term health risks that often go unaddressed. According to experts, half of women with PMOS will develop type 2 diabetes by age 40, and the condition increases the risk of cardiovascular events including high blood pressure, stroke, and heart attack.

"People don't realize, in addition to weight gain, half of women with PCOS will develop type 2 diabetes by age 40. And with PCOS, there's an increased risk of cardiovascular events, like hypertension, stroke, and heart attack," noted Lynsey Johnson, DNP, FNP-C, founder and CEO of PCOS Sisters Telehealth Clinic and Wellness Center.

Lynsey Johnson, DNP, FNP-C, Founder and CEO of PCOS Sisters Telehealth Clinic and Wellness Center

This reality underscores why treating PMOS as a metabolic disorder, rather than focusing solely on reproductive outcomes, is critical for long-term health.

How Has PMOS Treatment Evolved?

Treatment approaches have shifted significantly over the past few decades. Historically, doctors performed ovarian wedge resection surgery. Later, oral contraceptives became standard to suppress androgen production and regulate menstrual cycles. When insulin resistance was recognized as central to PMOS, metformin (a type 2 diabetes medication) was added to treatment regimens starting in the late 1990s and early 2000s.

Metformin improves insulin resistance and can help with menstrual regularity and androgen levels, but it has not been shown to produce significant weight loss. As obesity rates have risen in the general population, PMOS symptoms have become more severe and appear earlier in women's lives.

What Do Clinical Trials Show About GLP-1s for PMOS?

GLP-1 receptor agonists, a class of medications originally developed for type 2 diabetes, have emerged as a promising treatment for PMOS because they address both weight loss and metabolic dysfunction. Dr. Elkind-Hirsch led multiple clinical trials investigating these drugs in women with obesity and PMOS.

• Liraglutide Study (2022): Published in Fertility and Sterility, this trial found that liraglutide, a GLP-1 medication, was superior to placebo in reducing body weight and improving cardiovascular and metabolic markers in women with obesity and PMOS.
• Combination Therapy Study (2021): Published in The Journal of Clinical Endocrinology and Metabolism, this research compared two combination treatments. Both exenatide (a GLP-1) plus dapagliflozin (an SGLT2 inhibitor used for type 2 diabetes) and phentermine (an appetite suppressant) plus topiramate (an anticonvulsant) improved fasting glucose, testosterone, and blood pressure while reducing weight and total body fat. However, the GLP-1 combination was superior at improving blood glucose and insulin sensitivity.
• Adolescent Study (Unpublished): A trial led by Melanie Cree, MD, PhD, at the University of Colorado compared Rybelsus (an oral version of semaglutide) with dietary intervention over 4 months in girls aged 12 to 21 with obesity and PMOS. Although results have not yet been peer-reviewed, patients lost more weight with the GLP-1, and both treatments improved metabolic and reproductive measures.

The weight loss differences are striking. Patients on GLP-1s typically lose about 10 pounds per month and experience drops in testosterone levels, compared to only 1 or 2 pounds per month on metformin alone.

How Should PMOS Treatment Be Personalized?

Despite common symptoms, PMOS presents differently in different women. While as many as 80% of women with PMOS are overweight or obese, 20% are not. Some women experience hair thinning, acne, and chin hair instead of weight gain. Others have irregular periods and skin issues as their primary symptoms.

"PMOS does not look the same for everyone. It's important to ask patients, 'What is important to you?' Instead, I get so many reports of 16-year-olds being told they will never get pregnant. After leaving the clinic, that comment affects their mental health, body image, and self-worth," said Sasha Ottey, MHA, MLS (ASCP), founder and executive director of PCOS Challenge: The National Polycystic Ovary Syndrome Association.

Sasha Ottey, MHA, MLS (ASCP), Founder and Executive Director of PCOS Challenge: The National Polycystic Ovary Syndrome Association

Experts recommend tailoring treatment to each patient's priorities and symptoms. This may include referrals to dietitians, nutritionists, therapists, or psychiatrists depending on the individual's needs. Today, most people with PMOS are treated with a combination of birth control, metformin, and/or semaglutide (a GLP-1 medication).

Steps to Take If You Think You Have PMOS

• Seek a Comprehensive Evaluation: Ask your doctor to assess not just reproductive symptoms but also metabolic markers like insulin resistance, glucose levels, and cardiovascular risk factors.
• Discuss Your Priorities: Be clear about what matters most to you, whether that's fertility, weight management, skin health, or reducing disease risk. Your treatment plan should reflect your goals.
• Consider Metabolic Treatments: If you have obesity or metabolic dysfunction, ask your doctor whether metformin, GLP-1 medications, or combination therapy might be appropriate for your situation.
• Access Multidisciplinary Support: Work with a team that may include your primary care doctor, an endocrinologist, a dietitian, and a mental health professional to address all aspects of the condition.

What Does the Name Change Mean?

In May 2026, The Lancet announced an official name change from polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS). This reflects a fundamental shift in how the medical community understands the condition: it is not primarily a disorder of the ovaries, but rather a metabolic disorder that disrupts multiple hormone systems and causes ovulatory disturbances and infertility.

While PMOS cannot be cured, the growing recognition of its metabolic nature has opened new treatment pathways. GLP-1 receptor agonists represent a significant advance because they target the root cause: insulin resistance. As obesity rates continue to rise and PMOS presentations become more severe, these medications offer hope for better outcomes and improved quality of life for millions of women.